Chimeric Antigen Receptor-Engineered T Cell Therapy in Acute Myeloid Leukaemia-Reference-Cited by-同舟云学术

Chimeric Antigen Receptor-Engineered T Cell Therapy in Acute Myeloid Leukaemia

Published:2018-09-04 Issue: Volume: Page:11-19
ISSN:2397-6764
Container-title:European Medical Journal
language:
Short-container-title:EMJ

Author:

Paubelle Etienne¹,Rocher Clément²,Julia Edith²,Thomas Xavier²

Affiliation:

1. Department of Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France; LBMC, ENS, CNRS UMR5239, Faculté de Médecine Lyon-Sud, Lyon, France

2. Department of Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France

Abstract

Acute myeloid leukaemia (AML) is a disease with a very poor outcome and remains an area of significant unmet need, necessitating novel therapeutic strategies. The progress made in the field of immunotherapy, in particular chimeric antigen receptor (CAR)-engineered T cells, has given rise to many hopes for pathologies such as B cell acute lymphoblastic leukaemia and B cell lymphoma, and many studies have attempted to translate these successes to AML. This review summarises the recent advances in, and defines an ideal target for, CAR T cell therapy in AML.

Publisher

European Medical Group

Subject

General Medicine

Reference99 articles.

1. Lowenberg B et al. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051-62.

2. Döhner H et al. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-52.

3. Grimwade D et al. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127(1):29-41.

4. Burnett A et al. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487-94.

5. Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127(1):62-70.